Argo Biopharma has dosed the first subject in its Phase I clinical trial assessing BW-50218, a siRNA therapeutic targeting the TTR protein.

The post Argo Biopharma begins dosing for Phase I BW-50218 trial appeared first on Clinical Trials Arena.